Literature DB >> 21681687

Spontaneous in vitro IL-6 production in various intestinal segments in patients with inflammatory bowel disease.

P Drastich1, L Frolova-Brizova, P Zanvit, J Spicak, H Tlaskalova-Hogenova.   

Abstract

Interleukin-6 (IL-6) plays an important role in regulation of intestinal inflammatory processes in inflammatory bowel disease (IBD). The levels of IL-6 in media from cultured biopsy samples were determined by ELISA in 14 Crohn's disease (CD) patients, 17 patients with ulcerative colitis (UC), and 24 healthy controls in terminal ileum, cecum, and rectum. Results were confirmed by measuring mRNA expression in selected patients. In CD patients, there were increased levels of IL-6 (expressed in picograms per milligram of biopsy tissue mass) in terminal ileum compared with controls (median, 617 vs. 90.4; p < 0.001). High IL-6 levels were found in the rectum of CD patients with active disease but normal endoscopic findings (791 vs. 131; p < 0.05). This result was confirmed by mRNA expression. There was a substantial increase of IL-6 levels in cultured cecal (median, 327 vs. 94.0; p < 0.001) and rectal mucosa (median, 282 vs.131; p < 0.05) but not in ileal mucosa of UC patients. In conclusion, IL-6 production was higher in IBD patients than in controls; it correlated with disease activity and varied among different intestinal segments. In clinically active CD patients without rectal involvement, high IL-6 levels in cultured rectal mucosa suggest immune stimulation even in the absence of macroscopic inflammation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21681687     DOI: 10.1007/s12223-011-0018-0

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  24 in total

1.  Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria.

Authors:  N Borruel; M Carol; F Casellas; M Antolín; F de Lara; E Espín; J Naval; F Guarner; J R Malagelada
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

Review 2.  Interleukin-6 trans-signaling in inflammatory bowel disease.

Authors:  Keiichi Mitsuyama; Michio Sata; Stefan Rose-John
Journal:  Cytokine Growth Factor Rev       Date:  2006-10-12       Impact factor: 7.638

Review 3.  The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.

Authors:  Karl-Josef Kallen
Journal:  Biochim Biophys Acta       Date:  2002-11-11

4.  Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6.

Authors:  R Daig; G Rogler; E Aschenbrenner; D Vogl; W Falk; V Gross; J Schölmerich; T Andus
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

5.  Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease.

Authors:  J M Reimund; C Wittersheim; S Dumont; C D Muller; J S Kenney; R Baumann; P Poindron; B Duclos
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

6.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

7.  Colonic mucosal interleukin-6 in inflammatory bowel disease.

Authors:  K Mitsuyama; E Sasaki; A Toyonaga; H Ikeda; O Tsuruta; A Irie; N Arima; T Oriishi; K Harada; K Fujisaki
Journal:  Digestion       Date:  1991       Impact factor: 3.216

8.  Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis.

Authors:  Lenka Frolova; Pavel Drastich; Pavel Rossmann; Klara Klimesova; Helena Tlaskalova-Hogenova
Journal:  J Histochem Cytochem       Date:  2007-11-26       Impact factor: 2.479

9.  High levels of proinflammatory cytokines, but not markers of tissue injury, in unaffected intestinal areas from patients with IBD.

Authors:  Alberto J León; Emma Gómez; Jose A Garrote; David Bernardo; Asterio Barrera; Jose L Marcos; Luis Fernández-Salazar; Benito Velayos; Alfredo Blanco-Quirós; Eduardo Arranz
Journal:  Mediators Inflamm       Date:  2009-07-30       Impact factor: 4.711

10.  Defective inflammatory response in interleukin 6-deficient mice.

Authors:  E Fattori; M Cappelletti; P Costa; C Sellitto; L Cantoni; M Carelli; R Faggioni; G Fantuzzi; P Ghezzi; V Poli
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

View more
  4 in total

1.  Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation.

Authors:  Rocío López-Posadas; Christoph Becker; Claudia Günther; Stefan Tenzer; Kerstin Amann; Ulrike Billmeier; Raja Atreya; Gionata Fiorino; Stefania Vetrano; Silvio Danese; Arif B Ekici; Stefan Wirtz; Veronika Thonn; Alastair J M Watson; Cord Brakebusch; Martin Bergö; Markus F Neurath; Imke Atreya
Journal:  J Clin Invest       Date:  2016-01-11       Impact factor: 14.808

2.  RNA Purity, Real-Time PCR Sensitivity, and Colon Segment Influence mRNA Relative Expression in Murine Dextran Sodium Sulfate Experimental Colitis.

Authors:  Bernardo Oldak; Mayra Cruz-Rivera; Ana Flisser; Fela Mendlovic
Journal:  J Biomol Tech       Date:  2018-07-13

3.  Sphingosine kinase 1 is regulated by peroxisome proliferator-activated receptor α in response to free fatty acids and is essential for skeletal muscle interleukin-6 production and signaling in diet-induced obesity.

Authors:  Jessica S Ross; Wei Hu; Bess Rosen; Ashley J Snider; Lina M Obeid; L Ashley Cowart
Journal:  J Biol Chem       Date:  2013-06-13       Impact factor: 5.157

4.  Protective effect of Limosilactobacillus fermentum HFY06 on dextran sulfate sodium-induced colitis in mice.

Authors:  Bihui Liu; Lei Yang; Ya Wu; Xin Zhao
Journal:  Front Microbiol       Date:  2022-09-12       Impact factor: 6.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.